Travere Therapeutics, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- TVTX
- CIK
- 0001438533
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOEric Dube, Ph.D. | Sep 21, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
CEO departs: Eric Dube, Ph.D.
Eric Dube, Ph.D., President and Chief Executive Officer of Travere Therapeutics, Inc., departs the role, effective December 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 21, 2026Role: President and Chief Executive Officer
- Executive appointment
CEO appointed: Bradley L. Campbell
Bradley L. Campbell was named President and Chief Executive Officer of Travere Therapeutics, Inc., effective December 1, 2026. Bradley L. Campbell succeeds Eric Dube, Ph.D.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 21, 2026Role: President and Chief Executive Officer
Last verified Nov 8, 2026